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Original Article
IntRoductIon
Chronic kidney disease (CKD) is a disease characterized 
by chronic renal structural and functional progressive 
injury.[1] As the end stage of various kidney diseases, CKD 
has a wide range of pathogenic factors such as hypertension, 
diabetes, atherosclerosis, metabolic disorders,[2] and virus 
infection.[3] Among these risk factors of CKD, vascular 
calcification (VC) is one of the important factors.[4,5] Recent 
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Background: Chronic kidney disease (CKD) is closely related to the cardiovascular events in vascular calcification (VC). However, little 
has known about the characteristics of kidney injury caused by VC. Fibroblast growth factor 21 (FGF21) is an endocrine factor, which takes 
part in various metabolic actions with the potential to alleviate metabolic disorder diseases. Even FGF21 has been regarded as a biomarker 
in CKD, the role of FGF21 in CKD remains unclear. Therefore, in this study, we evaluate the FGF21 on the kidney injury in VC rats.
Methods: The male Sprague‑Dawley rats were divided into three groups: (1) control group, (2) Vitamin D3 plus nicotine (VDN)‑induced 
VC group, (3) FGF21‑treated VDN group. After 4 weeks, the rats were killed and the blood was collected for serum creatinine, urea 
nitrogen, calcium, and phosphate measurement. Moreover, the renal tissues were homogenized for alkaline phosphatases (ALPs) activity 
and calcium content. The levels of FGF21 protein were measured by radioimmunoassay. The levels of β‑Klotho and FGF receptor 
1 (FGFR1) protein were measured by enzyme‑linked immunosorbent assay (ELISA). The structural damage and calcifications in aortas 
were stained by Alizarin‑red S. Moreover, the structure of kidney was observed by hematoxylin and eosin staining.
Results: The renal function impairment caused by VDN modeling was ameliorated by FGF21 treatment, inhibited the elevated serum 
creatinine and urea level by 20.5% (34.750 ± 4.334 μmol/L vs. 27.630 ± 2.387 μmol/L) and 4.0% (7.038 ± 0.590 mmol/L vs. 6.763 ± 0.374 
mmol/L; P < 0.01), respectively, together with the structural damages of glomerular atrophy and renal interstitial fibrosis. FGF21 treatment 
downregulated the ALP activity, calcium content in the kidney of VC rats by 42.1% (P < 0.01) and 11.7% (P < 0.05) as well as ameliorated 
the aortic injury and calcification as compared with VDN treatment alone group, indicating an ameliorative effect on VC. ELISA assays 
showed that the expression of β‑Klotho, a component of FGF21 receptor system, was increased in VDN‑treated VC rats by 37.4% (6.588 ± 
0.957 pg/mg vs. 9.054 ± 0.963 pg/mg; P < 0.01), indicating an FGF21‑resistant state. Moreover, FGF21 treatment downregulated the level 
of β‑Klotho in renal tissue by 16.7% (9.054 ± 0.963 pg/mg vs. 7.544 ± 1.362 pg/mg; P < 0.05). However, the level of FGFR1, the receptor 
of FGF21, kept unchanged under VDN and VDN plus FGF21 administration (0.191 ± 0.0376 ng/mg vs. 0.189 ± 0.032 ng/mg vs. 0.181 ± 
0.034 ng/mg; P > 0.05).
Conclusions: In the present study, FGF21 was observed to ameliorate the kidney injury in VDN‑induced VC rats. FGF21 might be a 
potential therapeutic factor in CKD by cutting off the vicious circle between VC and kidney injury.
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studies have shown that renal artery calcification is a vital 
risk factor for CKD and microalbuminuria.[6] Moreover, 
the correlation between renal artery calcification and 
renal artery atheromatosis, an important inducement of 
CKD, has also been confirmed.[7] With the characteristic of 
calcium and phosphorus depositing in vessel walls, VC is 
motivated by a phenotypic modulation from vascular cell to 
osteoblast‑like cell, which can be observed in many diseases 
including diabetes, atherosclerosis, and CKD.[8] In patients 
with CKD, clinical studies have found the morbidity of VC 
is much higher than healthy people, which results from the 
disorder of calcium and phosphorus metabolism caused by 
renal function impairment.[9‑11] Meanwhile, hypertension 
and intraglomerular high pressure due to VC, together 
with micro‑VC in kidney, may accelerate the progress of 
CKD.[12,13] As VC and CKD are in reciprocal causation,[14] 
inhibiting the calcification in kidney may be an important 
aspect to control CKD.
Differing from the traditional view of points that VC is a 
passive process, the latest study showed that the process of 
VC was similar to the process of skeleton formation.[6] In fact, 
VC is an active, preventable, and reversible process regulated 
by various cytokines.[6,15‑17] The pathological mechanism 
of VC mainly related to the increase of intracellular 
alkaline phosphatase (ALP) activity, the high expression of 
bone‑related proteins, and the transform of vascular smooth 
muscle cell phenotype.[10,18] Therefore, inhibition of the 
particular link in the process of VC may be beneficial for 
reversing the development of calcification‑related diseases. 
Although little research on the kidney injury resulted from 
VC was reported, there are still evidences which indicate 
that, in the animal model induced by Vitamin D3 plus 
nicotine (VDN), not only was there large and middle arterial 
VC but also the calcium overload and micro‑VC could 
be observed in kidney.[19] Thus, VC may be an important 
stimulus in the process of CKD.
Fibroblast growth factor 21 (FGF21) is a member of the 
FGF superfamily, which is predominantly generated in liver, 
then secreted into circulation, and could affect throughout 
the body.[20,21] By forming a trimer with the receptor FGF 
receptor 1 (FGFR1) and its cofactor β‑Klotho,[22] FGF21 
can activate downstream signaling pathways to exert an 
antagonistic effect on the apoptosis of vascular endothelial 
cells,[23] inhibiting atherosclerosis[24] and the calcification 
of vascular smooth muscle cells.[25] In CKD patients, the 
increased serum FGF21 level is regarded as a potential 
biomarker for kidney injury.[26] As renal excretion is regarded 
as a major route to eliminate FGF21 from circulation,[27] it 
is reasonable to hypothesize that FGF21 may involve in the 
regulation of the process of CKD.
Whether VC could cause kidney injury is unknown, and the 
function of high expression of FGF21 in CKD is still unclear. 
In this study, we evaluated the changes of the structure and 
function of kidney in VDN‑treated VC rats. In addition, 
the level of endogenous FGF21, β‑Klotho, and its receptor 
FGFR1 in VDN‑induced VC rats was determined. Then, 
exogenous FGF21 was administrated to clarify whether 
FGF21 inhibits the process of kidney injury in VC rats.
Methods
Ethical approval
The study was approved by the Institutional Animal Care 
and Use Committee of  the Capital Medical University. 
The experimental procedures and protocols performed in 
this study were in concordance with ethical approval for 
Animals' Model Research Committee of the Capital Medical 
University.
Materials and reagents
FGF21 was from Phoenix Pharmaceuticals (Belmont, CA, 
USA). Enzyme‑linked immunosorbent assay (ELISA) kit 
for β‑Klotho and FGFR1 was purchased from Cloud‑Clone 
Co. (Wuhan, Hubei, China). The ALP kit was from Jiancheng 
Biological Co. (Nanjing, Jiangsu, China). The calcium 
assay kit was from Zhongsheng Biosino Bio‑technology 
and Science INC (Beijing, China). The VDN was bought 
from Sigma‑Aldrich (St. Louis, MO, USA). The urea 
determination kit and creatinine determination kit were 
purchased from Zhongsheng Biosino Bio‑technology and 
Science INC (Beijing, China). The regents for calcium 
and phosphate determination were from North Beijing 
Xinchuangyuan seized Biological Technology Co. 
Ltd. (Beijing, China). Alzet Mini‑Osmotic Pumps, model 
2004, were from Durect Corp. (Cupertino, CA, USA). All 
other reagents were of analytical grade. 
Animal and treatments
Eight‑week‑aged male Sprague‑Dawley rats were 
purchased from the Laboratory Animal Center of Peking 
University (Beijing, China) and housed in standard 
laboratory temperature and humidity conditions with a 
12 h light/dark cycle. The rats were divided into three 
groups randomly (n = 8): control group (NC group), 
model group (VDN group), and FGF21 treatment 
group (VDN + FGF21 group). The preparation for 
the VC model was made as previously described.[28] 
Briefly, rats were intragastric administrated with nicotine 
(25 mg/kg in 5 ml peanut oil) plus injected with Vitamin 
D3 intramuscularly (3 × 105 U/kg) at 9 a.m. on day 1. The 
nicotine administration was repeated at 5 p.m. The modeling 
continued for 4 weeks. For FGF21 treatment, the rats were 
anesthetized by pentobarbital, and then an osmotic minipump 
was implanted subcutaneously. The VDN and VDN + FGF21 
group were infused with vehicle or FGF21 (70 µg·kg−1·d−1), 
respectively, by osmotic minipump for 4 weeks.[23] Rats in 
the control group received the injection of saline and oral 
gavage of peanut oil, together with the infusion of saline 
with minipump. 
Measurement of fibroblast growth factor 21 level in 
renal tissue
Briefly, the renal tissue (100 mg) was excised and 
immediately acidified with 1.0 mol/L acetic acid and then 
heated at 100°C for 10 min to inactivate proteases. Then, 
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the tissue was homogenized and centrifuged at 17,000 g 
for 20 min. Radioimmunoassay (RIA) was performed to 
measure tissue FGF21 content in supernatants by use of a 
commercial RIA kit (Phoenix Pharmaceuticals) according 
to the manufacturer’s instructions.
Measurement of serum urea nitrogen and creatinine
Before execution, the rats were anesthetized and the blood 
was collected by intracardiac puncture. The urea level in 
serum was measured by a urea determination kit using 
glutamate dehydrogenase method. Likewise, the serum 
creatinine level was measured by a creatinine determination 
kit according to the manufacturer’s instructions.
Measurement of serum calcium and phosphate
The levels of serum calcium and phosphate were 
measured by automatic biochemical analyzer (TOSHIBA 
TBA‑40FR, Japan) with supplementary reagents, 
respectively.
Hematoxylin and eosin staining for nephritic tissue
The nephritic tissue was fixed in 4% paraformaldehyde 
overnight, then embedded in paraffin, and sectioned for 
hematoxylin and eosin (H and E) staining. Briefly, the 
sections were stained by hematoxylin; after washing and 
treating with 1% acidic alcohol, the sections were stained 
by eosin. Then, the sections were washed, dehydrated, and 
treated by xylene before microscopy. The cross sections 
were evaluated by Olympus BX 50 microscope (Olympus 
Optical Tokyo, Japan).
Alizarin red staining for aortic tissues
For Alizarin‑red S staining, aortic slides were dehydrated, 
rinsed rapidly in distilled water, and placed in an Alizarin‑red 
S (Sigma, St. Louis, MO, USA) staining solution at room 
temperature for 30 min. When a red‑orange color appeared, 
any unbound stain was removed from the tissues, and then 
the tissues were photographed under an Olympus BX 50 
microscope.
Measurement of calcium content in kidney
The renal tissue was first dried at 55°C and weighed, then 
dissolved in HNO3, dried at 180°C, and re‑dissolved with 
a blank solution (27 nmol/L KCl and 27 µmol/L LaCl3). 
Calcium levels were determined by colorimetry through a 
reaction with o‑cresolphthalein complexon and normalized 
to renal tissues dry weight.[29]
Measurement of alkaline phosphatase activity in kidney
The renal tissues were homogenized in ice‑cold buffer 
(20 mmol/L HEPES, 0.2% NP‑40, and 20 mmol/L MgCl2, 
pH 7.4). After centrifugation at 8000 g for 10 min at 4°C, 
the protein content in supernatant was determined by the 
Bradford method. ALP activity was measured using the 
ALP activity assay kit according to the manufacturer’s 
instructions. Briefly, the 1 ml of supernatant was mixed with 
the reaction buffer and then incubated at 37°C for 15 min. 
After incubation, 1.5 ml of developer was added, and then 
the absorbance at 520 nm was recorded. The activity of 
ALP in each well was calculated from the standard curve. 
One unit was defined as 1 g tissue protein producing 1 mg 
phenol for 15 min.[30]
Enzyme‑linked immunosorbent assay for fibroblast 
growth factor receptor 1 and β‑Klotho in nephridial 
tissue
Briefly, 10 mg of nephridial tissue was homogenized at 4°C in 
PBS, and then the mixture was further treated by ultrasonication. 
After centrifugation at 5000 g for 5 min at 4°C, the protein 
content in supernatant was determined by the Bradford method. 
The level of FGFR1 and β‑Klotho in supernatants was measure 
by ELISA kit according to the manufacturer’s instructions.
Statistical analysis
All calculations were performed using GraphPad Prism 
version 5.0 statistical software (GraphPad Software, 
San Diego, CA, USA). The data were calculated as 
the mean ± standard deviation (SD) from at least three 
independent experiments and analyzed by a one‑way 
ANOVA. The Student’s t‑test was used when only two 
groups were compared. Difference was accepted at P < 0.05. 
A value of P < 0.05 was considered statistically significant, 
and a P < 0.01 was considered very statistically significant.
Results
Increased expression of fibroblast growth factor 21 in 
kidney tissue
First, we used RIA to detect the endogenous FGF21 in 
VDN‑induced VC rats. Results showed that the FGF21 
expression in kidney tissue of VDN group increased 
significantly compared to the control group by 2.44‑fold (0.248 
± 0.108 vs. 0.607 ± 0.317 ng/mg, P < 0.05), indicating that 
FGF21 may be involved in the regulation of kidney injury 
results from VC.
Fibroblast growth factor 21 ameliorated the renal 
function impairment in vascular calcification rats
To evaluate the protective effect of exogenous FGF21 
on renal function, the serum creatinine and urea were 
tested [Figure 1a and 1b]. The level of serum creatinine and 
urea increased dramatically in VDN group compared to the 
control group by 34.3% and 29.1% (P < 0.01), respectively, 
indicating that the renal function was damaged. Meanwhile, 
treatment with FGF21 inhibited the elevated serum creatinine 
and urea level by 20.5% and 4.0% (P < 0.01), respectively. 
Likewise, H and E staining showed a normal renal glomerulus 
structure in the control group. In contrast, VDN‑treated rats 
exhibited pathological changes characterized by glomerular 
atrophy (white arrow) and prominent renal interstitial 
fibrosis (yellow arrows) [Figure 1c]. The rats treated with 
FGF21 showed less structural lesions than VDN group. 
These results revealed that FGF21 could protect the renal 
injury in VC rats.
Fibroblast growth factor 21 attenuated calcification in 
the kidney of Vitamin D3 plus nicotine‑treated rats
We further investigated whether FGF21 decreased the 
calcification rate of kidney. Compared with the control group, 
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the calcium content was 36.1% (P < 0.01) higher in VC rats. 
FGF21 treatment significantly decreased the calcium level 
in renal tissue by 29.1% (P < 0.05) as compared with VDN 
treatment alone group [Figure 2a]. Besides VC rats showed 
increased ALP activity in kidney by 2.63‑fold (P < 0.01). 
FGF21 downregulated the VDN‑increased ALP activity in the 
renal tissue of rats by 42.1% (P < 0.01) [Figure 2b]. In addition, 
Alizarin‑red S staining showed thickened vessel walls, 
disordered elastic fibers, and widespread calcifications in aortas 
of VDN group [Figure 2e]. Decreased calcium‑phosphate salt 
deposition in FGF21‑treated VC aortas was further confirmed 
compared with the VDN rats [Figure 2e]. However, the serum 
calcium and phosphate level did not response neither to VDN 
nor to FGF21 treatment (P > 0.05) [Figure 2c and 2d].
Fibroblast growth factor 21 inhibited the expression of 
β‑Klotho in calcification kidney
FGF21 can only function by forming trimerization with 
FGFR1 and β‑Klotho, so the effect of VDN modeling 
and FGF21 treatment on the level of renal FGFR1 and 
β‑Klotho was further investigated. In accordance with 
endogenous FGF21 [Figure 3a], the β‑Klotho level in kidney 
increased significantly in VC rats by 37.4% (P < 0.01). 
FGF21 administration significantly suppressed the 
increase of β‑Klotho level compared to the VDN group by 
16.7% (P < 0.05). However, no change was observed in the 
level of renal FGFR1 in neither VDN nor VDN + FGF21 
treatment (P > 0.05) [Figure 3b]. These results indicated that 
not FGFR1 but β‑Klotho was involved in the regulation of 
kidney injury in VC model by FGF21.
dIscussIon
Administration of VDN to rat is a widely used modeling 
method to cause VC, in which calcium overload generally 
occurred in many tissues and organs including aorta, 
heart, and kidney.[28,31,32] In our research, structural and 
functional injuries in kidney were observed in VDN‑treated 
rat [Figure 1a–1c]. In addition, the VC biomarkers were 
also measured in renal tissue. ALP, an important marker 
for the early differentiation of osteoblast, plays a central 
role in ossification process.[33,34] Being similar with the 
calcium content, the increased level of ALP activity and 
calcium content in the renal tissue indicate that calcification 
is in progress in the kidney [Figure 2a and 2b]. However, 
no substantial change was observed in the blood calcium 
and phosphorus between model group and the control 
group, which indicated that the calcification in kidney 
was independent from blood calcium and phosphorus 
[Figure 2c and 2d]. Since the increase of serum calcium 
and phosphate level could be observed only in 4–5 Stage 
CKD, these results also demonstrated that, in VDN‑treated 
VC model, the kidney injury happened at early phase.[35]
At present, the change of serum FGF21 in CKD patients 
has already been observed, but the function of FGF21 in 
the process of renal damage was still unclear. In our study, 
an increased expression of endogenous FGF21 in kidney 
was observed in VDN rats, suggesting that FGF21 may be 
involved in the regulation of kidney injury and calcification. 
Therefore, exogenous FGF21 was administrated to VDN 
modeling rats. As shown in Figure 2a–2c, exogenous 
FGF21 can downregulate the serum creatinine and blood 
urea levels of the VC rats and reverse the kidney structural 
damage, which means FGF21 can alleviate the injury of 
the renal structure and function in VC rats. At the same 
time, the renal ALP activity and calcium content were also 
suppressed by FGF21 [Figure 2a and 2b]. These results 
demonstrated that FGF21 could protect the kidney from 
injury and calcification in situ. Meanwhile, the protective 
Figure 1: Effect of exogenous FGF21 on the blood creatinine level in VDN‑induced VC rats (n = 8; a); effect of exogenous FGF21 on the urea level 
in VDN‑induced VC rats (n = 8; b); effect of exogenous FGF21 on the histopathology of kidney in VDN‑induced VC rats (original magnification 
×200). The histological sections of kidney were stained by H and E. The pathologic changes of glomerulus atrophy were marked by white arrows 
and prominent renal interstitial fibrosis were marked by yellow arrows (c). *P < 0.01 compared with the normal control group. †P < 0.01 compared 
with the VDN group. FGF21: Fibroblast growth factor 21; VC: Vascular calcification; VDN: Vitamin D3 plus nicotine.
c
ba
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effect of FGF21 was independent of regulating serum 
calcium and phosphate.
As well known, FGF21‑FGFR1‑β‑Klotho tripolymer is 
essential for FGF21 to function.[22] In our study, different 
from the level of FGFR1, which kept unchanged under 
VDN and VDN + FGF21 administration, the level of renal 
β‑Klotho increased significantly in the model group, in 
accordance with the endogenous renal FGF21 [Figure 3a]. 
The high expression of renal FGF21 and β‑Klotho suggested 
a high activity of FGF21 signaling pathway in kidney, which 
is an FGF21‑resistant state under VDN administration. While 
exogenous FGF21 treatment can overcome this resistant state 
Figure 2: Effect of exogenous FGF21 on the renal calcium level in VDN‑induced VC rats (n = 6–8; a); effect of exogenous FGF21 on renal activity in 
VDN‑induced VC rats (n = 6–8; b); effect of exogenous FGF21 on serum level of calcium in VDN‑induced VC rats (n = 8; c); effect of exogenous 
FGF21 on serum level of phosphate in VDN‑induced VC rats (n = 8; d); effect of exogenous FGF21 in aortas of VDN‑induced VC rats by Alizarin‑red 
S staining (original magnification ×200; d). *P < 0.01 compared with the normal control group. †P < 0.05 compared with the VDN group. ‡P < 0.01 




Figure 3: Effect of exogenous FGF21 on the levels of renal β‑Klotho in the kidney of VDN‑induced VC rats (n = 8) by ELISA (a). Effect of 
exogenous FGF21 on the levels of renal FGFR1 in VDN‑induced VC rats (n = 8) by ELISA (b). *P < 0.01 compared with the normal control 
group. †P < 0.05 compared with the VDN group. FGF21: Fibroblast growth factor 21; VC: Vascular calcification; VDN: Vitamin D3 plus nicotine; 
ELISA: Enzyme‑linked immunosorbent assay.
ba
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and protect the kidney from injury. The similar result was 
also reported by Kim et al.[36] in the kidney of db/db mice, 
which may be partly due to db/db mice and VDN‑treated 
rats all belonging to the metabolic disorders model. These 
results indicate that β‑Klotho plays an important role in the 
activation of FGF21 signaling, which may be a key target for 
the treatment of the diseases with the feature of metabolic 
disorders. In fact, in our study, it is by activating FGF21 
signaling pathway that exogenous FGF21 ameliorates the 
FGF21 resistance and then impair the kidney injury in VDN 
rats.
In summary, kidney injury and calcification in situ were 
observed in VDN‑induced VC rats. At the same time, the 
increased level of endogenous FGF21 and β‑Klotho in 
kidney indicates a negative feedback regulation. Exogenous 
FGF21 treatment can ameliorate the kidney injury and 
calcification, indicating that FGF21 might be a potential 
therapeutic target in CKD by cutting off the vicious circle 
between VC and kidney injury.
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脏组织局部成纤维细胞生长因子21（Fibroblast growth factor 21，FGF21）、β‑Klotho及成纤维细胞生长因子受体1（Fibroblast 









钙含量42.1% (p < 0.01)及11.7% (p < 0.05)，并能减少主动脉损伤及钙化程度。这些结果表明，FGF21可以减轻血管钙化导致
的肾损伤。另外，作为FGF21三聚体的组成部分，ELISA结果显示，β‑Klotho在血管钙化大鼠中升高了37.4% (p < 0.01),预示
机体处于FGF21抵抗状态。而外源性给予FGF21后，大鼠肾脏组织β‑Klotho下调16.7% (p < 0.05)。但是FGF21的受体FGFR1在
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